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1. Introduction 
Human parechoviruses (HPeVs) belong to the family of Picornaviridae and have been 
recognized as a separate group on the basis of distinct molecular and biological properties 
since 1999. The identification of HPeV3 in 2004 and its association with neonatal sepsis and 
meningitis made it particularly clear that HPeVs are related to severe disease in infants. 
Molecular techniques are increasingly being used for the identification of HPeVs and with 
the increase in epidemiological and clinical data, HPeVs are now considered to be the 
second predominant cause of viral meningitis, following enteroviruses (EVs). This review 
focuses on the role of HPeVs, with particular notice to HPeV3, as a causative agent in viral 
meningitis as well as neonatal sepsis and encephalitis. Data on epidemiology, clinical 
manifestations, immunology and molecular and cellular biology, underlying the greater 
pathogenicity of this novel group of viruses as well as the diagnosis, management and 
treatment options will be discussed.  
2. Classification and biology of HPeV 
Human parechoviruses (HPeVs) belong to the large Picornaviridae family, comprising  small 
non-enveloped, single-stranded positive-sense RNA viruses infecting both humans and 
animals. The Picornaviridae family currently consists of 12 established genera as of 2011: 
Enterovirus, Parechovirus, Hepatovirus, Kobuvirus, Aphthovirus, Erbovirus, Teschovirus, 
Cardiovirus, Tremovirus, Sapelovirus, Avihepatovirus and Senecavirus. Many new genera such 
as the Cosavirus, Klassevirus and Aquamovirus have recently been proposed, and are awaiting 
genus/type classification (http://www.picornastudygroup.com/).  
HPeVs were first discovered in 1956 during a summer diarrhea outbreak in the USA by 
Wigand & Sabin et al. (1961) and originally classified within the Enterovirus genus as 
echovirus 22 and 23. This was based on their biology in cell culture, exhibiting a similar 
cytopathogenic effect (CPE) as enteroviruses (EVs), their clinical presentation and non-
pathogenicity in both mice and monkeys. Despite these similarities, subtle differences such 
as a slow progression of CPE of infected cells in cell culture and their more common 
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association with mild gastrointestinal disease, in comparison to the more severe symptoms 
reported for other enterovirus types, led to their description as atypical enteroviruses. Later, 
evident differences in genome organization and structure, divergence of encoded proteins 
and other biological properties (Hyypia et al., 1992; Stanway et al., 2000), prompted their 
reclassification in 1999 (Stanway et al., 1994; Stanway & Hyypia, 1999) as HPeV types 1 and 
2 within the genus Parechovirus. Almost half a century after the discovery of HPeV1 and 2, a 
third HPeV type was discovered in Japan (Ito et al., 2004) and since then the number of 
HPeV types increased rapidly with the development of more state-of-the-art molecular 
techniques. Up to date there are 16 HPeV types known (Table, Figure 1). The Parechovirus 
genus also comprises a second group of viruses isolated from rodents; the Ljungan viruses 
(Niklasson et al., 1999; Stanway et al., 2005). 
Type Strain Origin Reference 
HPeV1A Harris Ohio, USA Hyypia et al., 1992 
HPeV1B BNI-788 St Bonn, Germany Baumgarte et al., 2008 
HPeV 2 Williamson Ohio, USA Ghazi et al., 1998 
HPeV 3 A308/99 Aichi, Japan Ito et al., 2004 
HPeV 4 K251176-02 Amsterdam, the Netherlands Benschop et al., 2006b 
HPeV 5 CT86-6760 Connecticut, USA Oberste et al., 1998 
HPeV 6 NII561-2000 Niigata, Japan Watanabe et al., 2007 
HPeV 7 PAK5045 Badin, Pakistan Li et al., 2009 
HPeV 8 BR/217/2006 Salvador, Brazil Drexler et al., 2009 
HPeV 9 BAN2004-10902 Bangkok, Thailand Oberste et al., unpub. 
HPeV 10 BAN2004-10903 Bangkok, Thailand Oberste et al., unpub. 
HPeV 11 BAN2004-10905 Bangkok, Thailand Oberste et al., unpub. 
HPeV 12 BAN2004-10904 Bangkok, Thailand Oberste et al., unpub. 
HPeV 13 BAN2004-10901 Bangkok, Thailand Oberste et al., unpub. 
HPeV 14 451564  Amsterdam, the Netherlands Benschop et al., 2008c 
HPeV 15 BAN-11614 Bangkok, Thailand Oberste et al., unpub. 
HPeV 16 BAN-11615 Bangkok, Thailand Oberste et al., unpub. 
Table. HPeV prototype strains (http://www.picornastudygroup.com/) 
Like other picornaviruses, the HPeV genome is small containing approximately 7300 
basepares encoding for a single polyprotein flanked by 5´ and 3´ untranslated regions 
(UTRs) and a poly A tail at the 3’end (Figure 2) (Stanway & Hyypia, 1999).  
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Following virus entry, the RNA is directly translated into a long polyprotein, which is 
subsequently cleaved by the viral protease (3C) into three structural proteins (VP0, VP1 and 
VP3) forming the capsid structure and seven non-structural proteins (2A–2C and 3A–3D) that 
are needed for replication. In contrast to other picornaviruses, VP0 is not further cleaved into 
VP4 and VP2. Additionally, while VP0 is not antigenic in any other genera, the predominant 
antigenic sites of HPeV have been mapped to the N-terminal region of the VP0 protein (Joki-
Korpela et al., 2000). For HPeV1, additional antigenicity eliciting the production of neutralizing 
antibodies is found to be located at the C-terminal end of the capsid protein VP1, where the 
receptor binding motif arginine-glycine-aspartic acid (RGD) is located. 
HPeV1 PicoBank HPeV
HPeV1 BNI-788St
HPeV1 HARRIS
HPeV1 2007-863
HPeV6 BNI67-03
HPeV6 2005-823
HPeV6 NII561-2000
HPeV2 Williamson
HPeV5 CT-86-6760
HPeV5 T92-15
HPeV4 K251176-02
HPeV4 FUK2005-123
HPeV4 T75-4077
HPeV8 BR/217/2006
HPeV3 A308-99
HPeV3 CAN82853-01
HPeV7 PAK5045
HPeV14 451564
Ljungan Virus 145SL
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Fig. 1. Neighbour joining tree based on the complete VP1 gene of HPeV types 1-8 and 14 
(amino acid p-distance). Complete VP1 sequences for HPeV9-13 and 15-16 were unavailable 
at the time of publication. 
VP0 2AVP1 2C2BVP3
3B (VPg) 3’UTR
5’UTR 3Dpol3A 3Cpro
 
Fig. 2. HPeV genome. 
To allow efficient translation, most picornaviruses enable the majority of host cellular 
mRNA translation to be shut off by the non-structural protein 2A. However, there is little 
evidence that HPeVs elicit the same shut-off (Stanway et al., 1994).  
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Replication is driven by the RNA-dependent RNA polymerase (3Dpol) and involves RNA 
structures present on the 5’UTR (Nateri et al., 2000, 2002) and VP0 (cis-acting replication 
element (CRE)) (Al-Sunaidi et al., 2007) as well as the 2C protein (NTPase activity and RNA 
binding) (Samuilova et al., 2006). Following binding of the protein VPg (3B) at the 5’end, the 
positive stranded RNA is copied to produce negative stranded RNA, which in turn can be 
replicated back to positive stranded RNA needed for assembly and additional translation 
activity to produce virus particles.  
Finally, these particles are released from the cells. In most picornaviruses, virus release is 
achieved through capsid maturation by the cleavage of VP0 into VP2 and VP4. However, 
the cleavage of VP0 into VP2 and VP4 does not appear in parechoviruses and the manner of 
how maturation and virus release is achieved for HPeVs remains largely unknown 
(Stanway et al., 1994). Nonetheless, the external appearance of HPeV particles has proved 
consistent with the external appearance of other picornaviruses, most closely resembling 
Foot and Mouth Disease Virus (FMDV) in the Aphthovirus genus as has recently been shown 
by cryoelectron microscopy and image reconstruction (Seitsonen et al., 2010).  
3. HPeV infections, from mild to severe disease  
Clinical symptoms of HPeV infections are generally similar to those found in EV infections 
ranging from mild respiratory and gastrointestinal disease to more severe disease like 
meningitis and sepsis-like illness. In earlier decades when only HPeV1 and 2 were known, 
HPeV infections were considered of little clinical importance. Even though occasionally, 
severe disease was reported for HPeV such as acute flaccid paralysis, myocarditis, 
meningitis, encephalitis and encephalomyelitis (Benschop et al., 2006a; Figueroa et al., 1989; 
Koskiniemi et al., 1989; Legay et al., 2002; Maller et al., 1967) the majority of HPeV1 
infections caused mild gastrointestinal and/or respiratory symptoms.  
This all changed with the discovery of HPeV3 (Ito et al., 2004). By comparing clinical data 
from children infected with HPeV1 and children infected with HPeV3, we showed the 
increased clinical relevance of this type. HPeV3 infections were predominantly associated 
with neonatal sepsis and CNS infections while children infected with HPeV1 had milder 
symptoms (Benschop et al., 2006a). These findings were later confirmed by others, 
increasingly detecting this type in the CSF of children with CNS disease, such as meningitis 
and encephalitis, as well as neonatal sepsis (Harvala et al., 2009; Levorson et al., 2009; van 
der Sanden et al., 2008; Verboon-Maciolek et al., 2008a; Wolthers et al., 2008).  
Children infected with HPeV3 often present with symptoms of fever and irritability as a 
sign of CNS infection, either meningitis or encephalitis. The majority (54-80%) of the 
children also show sepsis-like illness, defined as fever or hypothermia with signs of 
circulatory and/or respiratory dysfunction defined by tachycardia or bradycardia, low 
blood pressure and/or decreased saturation (Benschop et al., 2006a; Harvala et al., 2009; 
Selvarangan et al., 2011; Wolthers et al., 2008). Additional clinical symptoms frequently seen 
in HPeV3 infections are maculopapular rash, gastrointestinal symptoms and respiratory 
symptoms (Benschop et al., 2006a; Selvarangan et al., 2011; Verboon-Maciolek et al., 2008a; 
Wolthers et al., 2008).  
Severe clinical manifestations are mainly described in relation to HPeV3 infections, although 
occasionally other HPeV genotypes have been associated with serious illness (Schnurr et al., 
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1996; Watanabe et al., 2007). However, similarly to HPeV1 and 2, newer types have mainly 
been associated with mild gastro-intestinal and respiratory symptoms in children and are 
often found in children with an underlying illness (Pajkrt et al., 2009).  
4. Epidemiology of HPeV in relation to CNS infections 
Because HPeVs are reported as being transmitted through the fecal-oral route, 
epidemiological studies are often performed on stool samples and provide an accurate 
estimation of the prevalence of the different types. HPeV1 is considered as the predominant 
strain mainly affecting young children (Baumgarte et al., 2008; Benschop et al., 2006a, 2008c, 
2010a; Harvala et al., 2008; Joki-Korpela & Hyypia, 1998; Stanway et al., 2000; Tapia et al., 
2008; Watanabe et al., 2007). Epidemiological studies dating back over 30 year ago, showed 
HPeV1 to be widely spread (Ehrnst & Eriksson, 1993; Grist et al., 1978; Joki-Korpela & 
Hyypia, 1998; Khetsuriani et al., 2006b). In recent studies, involving the detection of the 
newer HPeV types, the new HPeV type 3 is identified as the second predominant strain 
(Benschop et al., 2006a, 2008c, 2010a; Ito et al., 2010; Tapia et al., 2008; Watanabe et al., 2007). 
HPeV3 comprised 22 to 26% of the HPeV types identified in HPeV positive stool samples 
collected in the Amsterdam region, while the majority of the HPeV positive stool samples 
comprised HPeV1 (65-71%)(Benschop et al., 2006a, 2008c, 2010a). Similar data were found in 
studies on stool samples in other European countries (Baumgarte et al., 2008; Tapia et al., 
2008), and Asia (Ito et al., 2010; Pham et al., 2010, 2011a; Watanabe et al., 2007) where HPeV1 
was identified as the most prevalent type, followed by HPeV3. HPeV4 is frequently found in 
stools as well (Benschop et al., 2008c, 2010a; Boros et al., 2010; Pham et al., 2011b; Zhong et 
al., 2011), while HPeV6 seems to prevail as a secondary respiratory pathogen (Harvala et al., 
2008). Infections with HPeV2 and 5 are reported sporadically (Benschop et al., 2010a; Ehrnst 
& Eriksson, 1996; van der Sanden et al., 2008). Circulation patterns of the newly reported 
HPeV types 7–16 are yet to be determined (Benschop et al., 2008c, 2010a; van der Sanden et 
al., 2008). 
The distribution of HPeV types is significantly different when only CNS infections are taken 
into account. Screening of CSF samples show HPeV3 to be the dominant type found in 
children, in particular neonates (Benschop et al., 2008c; Harvala et al., 2009, 2011; Pineiro et 
al., 2010; Renaud et al., 2011; Selvarangan et al., 2011; Verboon-Maciolek et al., 2008a, 2008b; 
Watanabe et al., 2007; Wolthers et al., 2008). These infections account for approximately 3-
17% of CNS infections reported as meningitis or encephalitis (Harvala et al., 2009; Pineiro et 
al., 2010; Watanabe et al., 2007; Wolthers et al., 2008; Yamamoto et al., 2009), far exceeding 
the percentage of herpes simplex virus infections. In contrast, EV in CSF is still most 
frequently detected in these samples, with 14-19% positive cases each year in the summer 
(Harvala et al., 2011; Pineiro et al., 2010; Wolthers et al., 2008). This ranks HPeV as the 
second dominant pathogen of viral meningitis and encephalitis. HPeV1 infections are rarely 
described in CSF (Harvala et al., 2011); the other HPeV types have never been described in 
CSF.  
Of interest is that HPeV infections of the CNS circulate intermittently every 2-3 years, and 
always in the summer months. However, the circulation patterns seem to be geographically 
distinct. HPeV3 detected in both CSF and stool in Northern Europe is described most 
commonly every 2 years, in the summer period of the even years (Benschop et al., 2006a, 
2008c, 2010a; Ehrnst & Eriksson, 1993; Harvala et al., 2009; van der Sanden et al., 2008; 
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Wolthers et al., 2008). In contrast, HPeV3 infections in the USA occur most frequently in the 
uneven years every 2 years (Renaud et al., 2011; Selvarangan et al., 2011). Pineiro et al. (2010) 
described HPeV3 detection rates in Spain to peak in 2006 and 2009, suggesting a longer cycle 
of perhaps every 3 years. However more data are needed to confirm this circulation pattern. 
In Asia, where HPeV3 was first identified, HPeV3 epidemics are more dispersed over the 
years (Watanabe et al., 2007). This intermittent circulation is also described for EV types, e.g. 
echovirus 9 and 30 (Antona et al., 2007; Khetsuriani et al., 2006b), and is associated with the 
emergence of antigenic diverse genetic lineages or novel recombinants for which the 
community presumably is not immune protected (McWilliam Leitch et al., 2010). However, 
based upon the lower evolution rate and diversity of circulating HPeV3 strains (Benschop et 
al., 2010b; Calvert et al., 2010), diversification of HPeV into new lineages that are 
antigenically distinct is unlikely. The reason for the intermittent circulation of HPeV3 thus 
remains unclear.  
In contrast to HPeV3, HPeV1 circulates every year in high numbers in the fall and winter 
months in Europe and Asia (Benschop et al., 2006a, 2008c, 2010a; Ehrnst & Eriksson, 1993; 
Tauriainen et al., 2007; Watanabe et al., 2007). The same is described for HPeV4 and 6 
(Benschop et al., 2008c, 2010a; Harvala et al., 2008; Pajkrt et al., 2009). Again, not only in 
clinical sense, but also from a epidemiological point of view, HPeV3 behaves different from 
other HPeV types. 
5. Risk groups for HPeV infections 
While EVs generally affect individuals of all ages, more than 90% of HPeV infections have 
been described in children younger than 5 years of age, (Abed & Boivin, 2006; Baumgarte et 
al., 2008; Benschop et al., 2008c, 2010a; Chen et al., 2009; Grist et al., 1978; Khetsuriani et al., 
2006a, 2006b; Pham et al., 2010; Tapia et al., 2008). WHO data from 1967-1974 reported that 
94% of the HPeV1 infections were found in children < 4 years of age, of which 60% where < 
1 year of age. Only 2,6% were isolated from adults (Grist et al., 1978). A survey in Sweden 
(1966-1990) reported similar findings, where 92% of the 109 patients with an HPeV1 
infection were < 2 years old and only 1,8% were adults (Ehrnst & Eriksson, 1993). A more 
recent survey performed in the USA spanning over the years 1970 and 2005 reported 
approximately 95% of HPeV1 infection (n=880) to be from children <5 years of age. Children 
aged < 1 year with an HPeV1 infection were reported in 73% of the 880 infections 
(Khetsuriani et al., 2006b).  
In 2006, we demonstrated in an observational pediatric study that the median age of 
children infected with HPeV3 was 1.3 months. This was significantly lower than the median 
age of children infected with HPeV1 (6.6 months) (Benschop et al., 2006a). Since then, the 
majority of HPeV3 infections have been found in children under the age of 2 months, most 
frequently in neonates (Benschop et al., 2008a, 2008c; Harvala et al., 2009, 2011; Pineiro et al., 
2010; Renaud et al., 2011; Selvarangan et al., 2011; Verboon-Maciolek et al., 2008a; Watanabe 
et al., 2007; Yamamoto et al., 2009). This age difference in relation to the disease severity 
between the two HPeV types suggests that neonates in comparison to older children might 
be less protected against HPeV3 infection. Seroprevalence data showed that 95-99% of 
neonates had antibodies against HPeV1 which is most likely to be maternal (Joki-Korpela & 
Hyypia, 1998; Nakao et al., 1970; Stanway et al., 2000; Takao et al., 2001; Tauriainen et al., 
2007). The high HPeV1 seroprevalence thus suggests that the majority of infants should be 
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protected from HPeV1 infection early in life via maternal protection. However, this may not 
always be the case as suggested by Ehrnst et al. (1993). The seroprevalence decreased after 6 
months of age, only to rapidly increase among children older than 1-3 year of age to 95%. 
The low seropositivity from 6 months to 1-3 years is marked by an increase in infection 
frequencies among children in this age group, (Benschop et al., 2006a; Joki-Korpela & 
Hyypia, 1998; Stanway et al., 2000; Takao et al., 2001; Tauriainen et al., 2007). Seroprevalence 
rates among adults remained stable at 97-99% (Joki-Korpela & Hyypia, 1998; Stanway et al., 
2000; Tauriainen et al., 2007).  
For HPeV3, seroprevalence is approximately 70% among adults (Ito et al., 2004). Data on 
seroprevalence in neonates are not available, but the seroprevalence rate for children 
between 7-12 months is 15% which steadily increases to 91% in adolescent adults only to 
decline again to 56-87% in adults. This is in contrast to what is seen for HPeV1 where over 
97% of adults still have antibodies against HPeV1 (Joki-Korpela & Hyypia, 1998; Stanway et 
al., 2000; Tauriainen et al., 2007). Interestingly, seroprevalence among adults in the child-
bearing age (20-39 years) is the lowest (57-74%) (Ito et al., 2004). This may indicate that 
children are less protected through maternal antibodies specific for HPeV3, explaining the 
young age and increased disease severity of HPeV3 infected children in comparison to 
HPeV1 infected children. The reason for the lower seroprevalence of HPeV3 is presumably 
to be related to its proposed recent emergence in the late eighties, which suggests that 
HPeV3 circulation is not widespread enough to provide sufficient protection in the neonatal 
period through maternal antibodies (Calvert et al., 2010; Harvala et al., 2011). 
Despite the lower seroprevelance of HPeV3, infection with this type has not been reported 
in adults or older children (>5 years). HPeV1 infections in adults have been documented but 
only rarely, and usually in patients with an underlying immune deficiency (Wolthers et al., 
manuscript in preparation). This confirms that antibodies against HPeV1 protect the adult 
immune competent population. In this respect, with 20-30% of adults seronegative for 
HPeV3 antibodies, infection with this type in adults should be described as well. A possible 
explanation will be discussed in paragraph 7. 
6. Laboratory findings and diagnosis of HPeV infection  
Diagnosis of viral meningitis typically involves analysis of CSF and the establishment of an 
etiological agent. CSF analysis of HPeV infected children can show a mildly elevated 
leukocyte count, but in the majority of the children (especially neonates) pleiocytosis is not 
detected. Normal values for leukocyte cell count vary with age, and in general a higher 
value is accepted as normal in younger children. In a recent study normal values for 
leukocyte counts (under 95th percentile) in children younger than 56 days were redefined as 
<19/μl for infants aged 0-28 days and <9/μl for infants aged 29-56 days (Kestenbaum et al., 
2010). Furthermore, CSF glucose levels in children infected with HPeV are usually normal, 
while CSF protein levels can be normal or elevated (Pineiro et al., 2010; Selvarangan et al., 
2011; Verboon-Maciolek et al., 2008a; Wolthers et al., 2008); thus normal CSF findings 
therefore do not rule out an HPeV meningitis or encephalitis. 
Laboratory evaluation of blood from HPeV infected children typically shows a normal 
leukocyte blood count, although leukopenia is also reported in 33% of the children 
(Selvarangan et al., 2011). C-reactive protein remains low or slightly elevated (Pineiro et al., 
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2010; Verboon-Maciolek et al., 2008b; own observations). In some cases liver enzymes can be 
elevated, sometimes leading to hepatitis and liver necrosis (Levorson et al., 2009; 
Selvarangan et al., 2011; Verboon-Maciolek et al., 2008b).  
In children with signs of encephalitis cranial ultrasonography and MRI are useful for the 
detection of cerebral abnormalities. Cranial ultrasonography showed extensive 
periventricular echogenicity in one study of neonates with HPeV encephalitis (Verboon-
Maciolek et al., 2008a). MRI can demonstrate white matter abnormalities (Gupta et al., 2010; 
Verboon-Maciolek et al., 2008a). The severity of the imaging abnormalities correlated with 
neurodevelopmental problems later in age (Verboon-Maciolek et al., 2008a).  
Classically, HPeVs, like EVs, can be diagnosed through cell culture isolation, usually 
involving monkey kidney cells and human fibroblasts (Benschop et al., 2010a; Schnurr et al., 
1996). Other cell lines, such as the HT29 cell line (human colon adenocarcinoma cells), A549 
(human lung carcinoma cell line), RD (Rhabdomyosarcoma cells) can be used for culturing 
HPeV isolates as well (Abed & Boivin, 2006; Al-Sunaidi et al., 2007; Benschop et al., 2010a; 
Watanabe et al., 2007). However, cell culture has its limitations. As shown for culturing EVs, 
different HPeV types display difference in cell growth in various cell lines, and panels of at 
least three cell lines may be required to efficiently isolate the subsequent types from clinical 
material (Abed & Boivin, 2006; Benschop et al., 2010a; Watanabe et al., 2007). The colon 
carcinoma cell line HT29 was found to efficiently support the growth of HPeV1, 2, and 4-6. 
However, for the isolation of HPeV3, only a few specific cell lines (e.g. Vero and LLCMK2 
monkey kidney cells) were found to support the growth, albeit slow, of this type (Abed & 
Boivin, 2006; Benschop et al., 2010a; Watanabe et al., 2007). CPE produced by HPeV3 on 
these cells was scarce as well.   
In general, CPE produced by HPeVs is not significantly different from the CPE elicited by 
EVs and HPeVs can mistakenly be identified as EVs in the event specific serotyping is not 
routinely performed (Benschop et al., 2006a). This also explains the original classification of 
HPeVs as EVs (Wigand & Sabin, 1961). The neutralization EV-panel of specific antibodies 
only includes antisera against HPeV1 and 2 (Kapsenberg, 1988). Other HPeV types cannot 
be serotyped because antibodies are not available (HPeV3-6), or because they cannot be 
cultured at all (HPeV7-14).  
To isolate viruses from CSF, cell culture is proven to be less sensitive, as the load in patients 
with meningitis or encephalitis is fairly low ranging from 10 to 1000 TCID50 infectious virus 
per milliliter CSF (Rotbart, 2000). Therefore, PCR is the preferred method for detection of 
viruses in this material (Espy et al., 2006; Read et al., 1997; Romero 1999; Rotbart HA & 
Romero JR, 1995; van Doornum et al., 2007). But while with cell culture, both EVs and 
HPeVs can be diagnosed, PCR specific for EVs will fail to detect HPeVs because the targeted 
5’UTR is too diverse between HPeVs and EVs (Beld et al., 2004; Benschop et al., 2006a; 
Hyypia, 1989; Hyypia et al., 1989; Oberste et al., 1999). Therefore a separate RT-PCR 
specifically targeting the 5’UTR of HPeVs is required. Real-time RT-PCRs have been 
developed and validated for HPeV detection, which are faster, less laborious and with a 
lower contamination risk than conventional endpoint PCRs (Baumgarte et al., 2008; 
Benschop et al., 2008b; Corless et al., 2002; Nix et al., 2008; Noordhoek et al., 2008; Tapia et 
al., 2008). By genotyping methods targeting the variable capsid region VP1, positive CSF 
samples from infants with CNS associated disease, can be characterized directly from the 
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clinical material (Harvala et al., 2009; Verboon-Maciolek et al., 2008a). Direct genotyping 
from clinical material avoids secondary cell culture isolation of EV/HPeV from CSF, a 
material for which virus culture is already an insensitive method of detection (Romero, 1999; 
Rotbart & Romero, 1995).  
Pathogen detection in CSF is the strongest indicator of the pathogen’s association to the 
disease, but it is not uncommon to diagnose an EV or HPeV infection by detection of the 
virus in other clinical samples while the patient presents neurological symptoms (Benschop 
et al., 2006a). Several real-time PCRs for HPeV have been validated and tested on stool 
samples, and/or throat swabs (Baumgarte et al., 2008; Benschop et al., 2008c; Nix et al., 2008; 
Noordhoek et al., 2008; Tapia et al., 2008). The high viral loads in these samples make them 
suitable for diagnosis by cell culture as well. However, it should be taken into account that 
both HPeVs and EVs can be shed in high amount in stool and respiratory material, even 
after clearance of symptoms (Chung et al., 2001; Harvala et al., 2008). 
In summary, HPeV3, which is the most pathogenic HPeV type, and the most prevalent type 
detected in CNS disease, is difficult to grow in cell culture and is not routinely serotyped by 
the available antibody pools. Data on prevalence of HPeV types that rely on virus isolation 
by cell culture alone (Abed & Boivin, 2006; de Vries et al., 2008; van der Sanden et al., 2008; 
Watanabe et al., 2007) will be biased by the cell panel used for virus culture, the difference in 
growth characteristics between the HPeV types, and the inability of the newer HPeV types 
7-14 to grow in cell culture. Therefore, detection of HPeV for clinical or epidemiological 
purposes should rely on real-time PCR and subsequent genotyping based on VP1 or 
VP1/VP3.   
7. Pathogenesis 
It is not known why HPeV3 is more associated with severe neonatal sepsis and CNS disease 
in infants in comparison to other HPeV types. But several serological as well as biological 
and genomic features of HPeV3 in conjunction with preliminary experimental data may 
provide clues as to why this type has a neurovirulent phenotype and is predominantly 
identified among neonates.  
7.1 Host immune response to HPeV 
The defense mechanisme against HPeV meningitis/encephalitis or HPeV infections in 
general is largely unknown. Most of what we know from picornavirus immunity is distilled 
from immunological studies with EV infections. An efficient host response against EVs is 
most likely dependent on a proper humoral immune response with release of neutralizing 
antibodies. This is underlined by the increased incidence of severe EV infections in patients 
with primary antibody deficiency (PID), such as X-linked agammaglobulinemia (XLA), in 
which chronic enteroviral meningoencephalitis (CEMA) is one of the most severe 
complications (Moin et al., 2004; Plebani et al., 2002; Wildenbeest et al., 2011). In a recent 
survey in the USA, a mortality rate of 35% was reported in patients with PID due to chronic 
or disseminated EV infections and 40% of the survivors of the initial illness had long-term 
neurological symptoms (Halliday et al., 2003). In this large survey echovirus 11 was the 
most common EV type identified and the CNS was nearly always involved. Interestingly, 
changes in CSF parameters, such as elevated CSF protein levels did not correlate with 
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changes in neurological signs and symptoms. Successful treatment with therapeutic 
immunoglobulin therapy (e.g. intravenous immunoglobulins (IVIG)) in PID patients with  
an EV meningitis/encephalitis provides additional evidence for an important role  
of neutralizing antibodies for an adequate host immune response in EV 
meningitis/encephalitis. In neonates, characterized by an impaired humoral immune 
response, lack of specific maternal EV antibodies is shown to be a risk factor for the 
development of severe illness (Abzug, 2004). 
Knowledge of the host immune response to HPeV is in comparison to EV even more 
limited. In contrast to the evidence as described in the section above, there are no data 
available on the protective role of neutralizing antibodies in HPeV infections. The lower 
seroprevelance of HPeV3 in adults might suggest a lack of maternal protection in the early 
months of life. To study the protective role of these antibodies against both HPeV1 and 3 
infections, our group has set up a case-control study of neonates and children < 1 year that 
is currently ongoing. 
Only recently, toll like receptors (TLR) 7 and 8 were identified as important key players  
in the innate immune defense against HPeV1 (Triantafilou et al., 2005). TLRs are 
transmembrane proteins that play an important role in immune responses against microbial 
pathogens, by inducing inflammatory cytokines in response to bacteria and viruses. 
Although never published, one can assume that these TLRs are equally important in the 
defense against HPeV3 infections. Volpe (2008) suggested that HPeV3 infections could result 
in intracellular binding of TLR8, leading to the release of reactive oxygen and nitrogen and 
pro-inflammatory cytokines from microglia and as a result neural cell death. Interestingly, 
TLR8 is specifically distributed in axonal perturbations and only in the developing nervous 
system which could explain why we specifically observe the severe HPeV3 infections in 
infants rather than among older children and adults.  
7.2 Cell tropism & receptor interactions  
The specific detection of HPeV3 in CSF might direct towards a difference in cell tropism 
between HPeV types. This is already reflected by the slow growth of HPeV3 on a limited 
number of cell lines and its poor production of CPE (Abed & Boivin, 2006; Benschop et al., 
2010a; Watanabe et al., 2007). That HPeV3 infects other cell lines than for example HPeV1, is 
underlined by recombination studies done in our laboratory. HPeV3 recombination is 
highly limited, while other HPeV types frequently recombine with each other (Benschop et 
al., 2008d, 2010b; Calvert et al., 2010). This indicates that HPeV3 rarely gets into contact with 
other types in the same cell where recombinants are produced during replication of the 
infected viruses. 
The difference in tropism can be explained by a difference in receptor usage. HPeV types 1, 
2, and 4-6 contain an RGD motif in the C-terminus of VP1 that is utilized by several other 
viruses, such as FMDV, Coxsackie A virus 9 and echovirus 9, for their attachment to cell 
surface integrins. The RGD motif is essential for HPeV1 infection (Boonyakiat et al., 2001; 
Joki-Korpela et al., 2001; Pulli et al., 1997; Stanway et al., 2000). However, HPeV3 does not 
contain an RGD motif and thus it is assumed that infection of HPeV3 is established via a 
different receptor that is RGD independent, but is as yet unknown. Based on receptor 
studies of different EV types we also know that the cell surface expression of receptors 
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during organ development plays a major role in defining tropism (Harvala et al., 2005; 
Scassa et al., 2011; Yamayoshi et al., 2009). This shift of specific cell receptor expression 
during development would support the observation that HPeV3 infections are rarely or 
never seen in older children and adults and could partly explain why neonates are more 
prone for HPeV3 infections.  
8. Treatment 
There is no antiviral treatment against HPeVs currently available (Wildenbeest et al., 2010). 
Therefore, supportive treatment and administration of IVIG are the only available options. 
IVIG is sometimes given to neonates to reduce disease burden from EV infection, although 
its efficacy has not been proven. Neutralizing EV antibody (nAb) titers in IVIG vary between 
batches and geographic regions (Cao et al., 2010; Galama et al., 1997; Planitzer et al., 2011). 
For therapeutic purposes, high nAb titers against the specific serotype might be needed 
(Abzug et al., 1995). The seroprevalence rates of HPeV1 and HPeV3 found in adults would 
suggest IVIG to contain moderate to high titers of nAbs against these HPeV types. A case-
report of a twin with neonatal sepsis and hepatitis infected with HPeV3 showed one child to 
have recovered after having received IVIG (Al Maamari et al., 2009). However, data on IVIG 
titers against HPeV3 was not given in this study. We found high HPeV1-specific nAb in two 
batches of IVIG, but low nAb titers against HPeV3 in these IVIG batches (Westerhuis et al., 
manuscript in preparation; Wildenbeest et al., 2011). Therefore, IVIG might be beneficial in 
the treatment of HPeV1 infections and less effective in the treatment of HPeV3, although 
more data are needed. Moreover, the dispersed circulation of HPeV3 could have effect on 
the nAb titers in IVIG batches collected in different years and should be taken into account. 
Recently, a case report was published on the use of pleconaril in a patient with HPeV-
associated enteropathy (van de Ven et al., 2011). Pleconaril inhibits viral replication by 
integration into the hydrophobic pocket inside the viral capsid. As a result, uncoating and 
binding of the virus to the host cell are interrupted (Pevear et al., 1999). The hydrophobic 
pocket is relatively well preserved among EVs and HRVs, resulting in a broad-spectrum 
anti-enteroviral and -rhinoviral activity of pleconaril. However, the capsid of HPeVs is 
different (Stanway et al., 2000; Seitsonen et al., 2010), indicating that the hydrophobic pocket 
differs from that of EVs. Indeed data from our laboratory show that HPeV1 and HPeV3 are 
resistant against pleconaril in vitro (Wildenbeest et al., 2010). In agreement, pleconaril did 
not have any effect on replication of an unspecified HPeV found in the patient with 
enteropathy, nor did ribavirin (van de Ven et al., 2011).   
In summary, no systematic data are available on HPeV treatment, and clinical experience 
with severity and treatment of HPeV infections is just beginning to build up. Treatment 
options for HPeV and the related EV are urgently needed. In the meantime, administration 
of IVIG is the only option.  
9. Concluding remarks: HPeV3 infection of the CNS 
Before the turn of the century, HPeVs infections were described as mild infections in 
children. At that time only two types were known, and severe symptoms were occasionally 
reported. With the discovery of a third HPeV type (HeV3), the view on HPeVs as relevant 
pathogens in viral CNS infections such as meningitis and encephalitis has changed 
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drastically. While various EV types are known to be commonly involved in meningitis, 
(echovirus 9 and 30, EV71 and CBV5), of the 16 HPeV types currently described, HPeV3 is 
the primary type to cause CNS disease in children. 
The introduction of rapid PCR detection for both EVs and HPeVs in CSF demonstrate that 
both viruses play an important role in the pathogenesis of meningitis/encephalitis. 
Increased routine screening of HPeVs will lead to an increase in the identification of HPeV 
infected children and a decrease in the use of antibiotics. Differences in maternal protection 
and its genetic make up in relation to its biological characteristics should provide clues in 
the near future on how HPeV3 type specifically infects the CNS of particularly newborns. 
This will aid in the development of new treatment options that will allow effective care of 
these children, possibly preventing neurological sequelae in these children. 
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